BioVaxys Technology Corp. (BVAXF)
USD 0.05
(7.06%)
USD 0.05
(7.06%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -977.00 CAD | 99.31% |
| 2022 | -141.89 Thousand CAD | 76.08% |
| 2021 | -593.11 Thousand CAD | 75.52% |
| 2020 | -2.42 Million CAD | -958.21% |
| 2019 | -228.98 Thousand CAD | -1363.22% |
| 2018 | -15.64 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -94.77 Thousand CAD | 89.07% |
| 2024 Q1 | -867.01 Thousand CAD | -88642.07% |
| 2024 Q3 | -409.63 Thousand CAD | -332.21% |
| 2023 Q1 | -71.61 Thousand CAD | 49.53% |
| 2023 FY | -977.00 CAD | 99.31% |
| 2023 Q3 | -423.00 CAD | 98.51% |
| 2023 Q4 | -977.00 CAD | -130.97% |
| 2023 Q2 | -28.47 Thousand CAD | 60.23% |
| 2022 Q1 | -148.99 Thousand CAD | 74.88% |
| 2022 Q2 | -113.57 Thousand CAD | 23.77% |
| 2022 Q4 | -141.89 Thousand CAD | -263.39% |
| 2022 FY | -141.89 Thousand CAD | 76.08% |
| 2022 Q3 | -39.04 Thousand CAD | 65.62% |
| 2021 Q4 | -593.11 Thousand CAD | 19.93% |
| 2021 Q3 | -740.7 Thousand CAD | 46.32% |
| 2021 Q2 | -1.37 Million CAD | -61.0% |
| 2021 Q1 | -857.1 Thousand CAD | 64.63% |
| 2021 FY | -593.11 Thousand CAD | 75.52% |
| 2020 Q1 | -210.32 Thousand CAD | 8.15% |
| 2020 FY | -2.42 Million CAD | -958.21% |
| 2020 Q4 | -2.42 Million CAD | -290.75% |
| 2020 Q3 | -620.12 Thousand CAD | -269.27% |
| 2020 Q2 | -167.93 Thousand CAD | 20.16% |
| 2019 FY | -228.98 Thousand CAD | -1363.22% |
| 2019 Q4 | -228.98 Thousand CAD | 12.41% |
| 2019 Q2 | -303.64 Thousand CAD | 9.35% |
| 2019 Q1 | -334.96 Thousand CAD | 0.0% |
| 2019 Q3 | -261.43 Thousand CAD | 13.9% |
| 2018 FY | -15.64 Thousand CAD | 0.0% |
| 2018 Q3 | -970.00 CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 100.006% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 100.024% |
| SQZ Biotechnologies Company | -36.23 Million USD | 99.997% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 100.002% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 99.985% |
| Mesoblast Limited | 55.85 Million USD | 100.002% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 100.105% |
| Genus plc | 190.6 Million USD | 100.001% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 100.044% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 100.08% |
| Marizyme, Inc. | 18.56 Million USD | 100.005% |
| ContraFect Corporation | -6.02 Million USD | 99.984% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 100.144% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 100.726% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 100.085% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 100.044% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 100.018% |
| MultiCell Technologies, Inc. | 90.04 USD | 1185.073% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 99.867% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 100.008% |
| EV Biologics, Inc. | 1.36 Million USD | 100.071% |
| Q BioMed Inc. | 4.06 Million USD | 100.024% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 100.003% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 100.157% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 100.097% |
| Biomind Labs Inc. | 711.4 Thousand USD | 100.137% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 100.001% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 100.008% |
| Skye Bioscience, Inc. | -5.72 Million USD | 99.983% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 100.114% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 100.699% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 100.017% |
| IMV Inc. | 7.67 Million USD | 100.013% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 104.918% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 100.044% |
| GB Sciences, Inc. | 1.74 Million USD | 100.056% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 99.468% |
| HST Global, Inc. | 96.79 Thousand USD | 101.009% |
| CSL Limited | 10.52 Billion USD | 100.0% |
| Halberd Corporation | 144.72 Thousand USD | 100.675% |
| Enzolytics Inc. | 981.65 Thousand USD | 100.1% |
| Resverlogix Corp. | 6.45 Million USD | 100.015% |
| Affymax, Inc. | -5.59 Million USD | 99.983% |
| SYBLEU INC | 473.71 Thousand USD | 100.206% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 99.855% |
| argenx SE | -2.02 Billion USD | 100.0% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 100.002% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 99.998% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 100.036% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 99.989% |
| AVAX Technologies, Inc. | -5.9 Million USD | 99.983% |
| Zenith Capital Corp. | 10.06 Thousand USD | 109.708% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.0% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 100.487% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 100.041% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 100.594% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 100.002% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 100.049% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | 99.962% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 100.272% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 100.005% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 94.666% |
| BioStem Technologies, Inc. | 4.47 Million USD | 100.022% |
| ONE Bio Corp. | 9.04 Million USD | 100.011% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 100.485% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 25.42% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 100.474% |
| Agentix Corp. | 37.63 Thousand USD | 102.596% |
| LadRx Corporation | -2.03 Million USD | 99.952% |
| Cell Source, Inc. | 9.23 Million USD | 100.011% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 95.213% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 100.154% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 100.154% |
| NovAccess Global Inc. | 2.17 Million USD | 100.045% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 100.014% |
| Itoco Inc. | 228.3 Thousand USD | 100.428% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 100.718% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 100.02% |
| Kadimastem Ltd | -253.1 Thousand USD | 99.614% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 100.243% |
| CytoDyn Inc. | 20.26 Million USD | 100.005% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -51.005% |
| Mobile Lads Corp. | 484.23 Thousand USD | 100.202% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 89.459% |
| Qrons Inc. | 351.42 Thousand USD | 100.278% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 100.013% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 99.609% |
| Rebus Holdings, Inc. | 305 Thousand USD | 100.32% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 100.022% |
| International Stem Cell Corporation | 2.59 Million USD | 100.038% |
| Bioxytran, Inc. | 1.89 Million USD | 100.051% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 101.565% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 100.045% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 100.028% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 100.011% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 100.126% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 99.922% |
| Neutra Corp. | 52.18 Thousand USD | 101.872% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 99.961% |
| PureTech Health plc | -167.19 Million USD | 99.999% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 99.601% |
| IXICO plc | -4.44 Million USD | 99.978% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 100.007% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 100.002% |
| CSL Limited | 10.52 Billion USD | 100.0% |
| Cellectis S.A. | -43.81 Million USD | 99.998% |